ENTITY
Xiangcai Co.
Xiangcai Co.
PulseAugur coverage of Xiangcai Co. — every cluster mentioning Xiangcai Co. across labs, papers, and developer communities, ranked by signal.
Total · 30d
3
3 over 90d
Releases · 30d
0
0 over 90d
Papers · 30d
0
0 over 90d
TIER MIX · 90D
SENTIMENT · 30D
1 day(s) with sentiment data
RECENT · PAGE 1/1 · 2 TOTAL
-
Hengrui Medicine subsidiaries get drug trial approvals; Xiangcai merger review resumes
Hengrui Medicine announced that its subsidiaries have received approval from China's National Medical Products Administration for clinical trials of three drugs. These include SHR-3821 for advanced solid tumors, Adebeli…
-
Shanghai Stock Exchange Resumes Review of Xiangcai's Dazhihui Acquisition
The Shanghai Stock Exchange has resumed its review of Xiangcai Co.'s proposed acquisition of Shanghai Dazhihui Co. through a share swap. The review was previously halted due to an expired valuation report and outdated f…